Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis

被引:18
作者
Liegeon, Geoffroy [1 ]
Antoni, Guillemette [2 ]
Pialoux, Gilles [3 ]
Capitant, Catherine [2 ]
Cotte, Laurent [4 ]
Charreau, Isabelle [2 ]
Tremblay, Cecile [5 ]
Cua, Eric [6 ]
Senneville, Eric [7 ]
Raffi, Francois [8 ,9 ]
Meyer, Laurence [2 ,10 ]
Molina, Jean-Michel [1 ,11 ,12 ]
机构
[1] Hop St Louis, Assistance Publ Hop Paris, Paris, France
[2] INSERM, Villejuif, France
[3] Hop Tenon, Paris, France
[4] Hosp Civils Lyon, Hop Croix Rousse, Lyon, France
[5] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[6] Hop Archet, Nice, France
[7] Ctr Hosp Univ Tourcoing, Hop G Dron, Tourcoing, France
[8] Nantes Univ, INSERM, UIC 143, Nantes, France
[9] Ctr Hosp Univ Hotel Dieu, Serv Malad Infect, Nantes, France
[10] Univ Paris Sud, Paris Saclay, France
[11] Univ Paris Diderot Paris 7, Sorbonne Paris Cite, Paris, France
[12] INSERM, UMR 944, Paris, France
关键词
PrEP; on-demand; intermittent; kidney; eGFR; tenofovir; HIV; RENAL-FUNCTION; ANTIRETROVIRAL PROPHYLAXIS; TUBULAR DYSFUNCTION; BANGKOK TENOFOVIR; INFECTION; RISK; PREVENTION; EXPOSURE; FUMARATE/EMTRICITABINE; REVERSIBILITY;
D O I
10.1002/jia2.25420
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is associated with a small but statistically significant decrease in estimated glomerular filtration rate (eGFR). We assessed the renal safety of on-demand PrEP with TDF/FTC in HIV-1 uninfected men. Methods We used data from the randomized double-blind placebo-controlled ANRS-IPERGAY trial and its open-label extension conducted between February 2012 and June 2016 among HIV-uninfected MSM starting on-demand PrEP. Using linear mixed model, we evaluated the mean eGFR decline from baseline over time and determined risks factors associated with eGFR decline during the study. Results During the blind phase, with a median follow-up of 9.4 months, the mean decline slope of eGFR from baseline was -0.88 and -1.53 mL/min/1.73 m(2) per year in the placebo (n = 201) and the TDF/FTC group (n = 198) respectively, with a slope difference of 0.65 mL/min/1.73 m(2) per year (p = 0.27). Including both phases, 389 participants started on-demand TDF/FTC with a median follow-up of 19.2 months and a mean decline of eGFR from baseline of -1.14 mL/min/1.73 m(2) per year (p < 0.001). The slope of eGFR reduction was not significantly different in participants with baseline eGFR <= 90 mL/min/1.73 m(2) (p = 0.44), age >40 years (p = 0.24) or hypertension (p = 0.21). There was a dose-response relationship between recent tenofovir exposure and lower eGFR when considering the number of pills taken in the two months prior the visit (eGFR difference of -0.88 mL/min/1.73 m(2) between >15 pills/month vs. <= 15 pills/month, p < 0.01) or plasma tenofovir concentrations at the visit (eGFR difference compared to <= 2 ng/mL: >2 to <= 10ng/mL: -0.98 mL/min/1.73 m(2), >10 to <= 40ng/mL: -1.28 mL/min/1.73 m(2), >40 ng/mL: -1.82 mL/min/1.73 m(2), p < 0.001). Three participants discontinued TDF/FTC for eGFR < 60 mL/min/1.73 m(2) during the OLE phase. No case of Fanconi syndrome was reported. Conclusions The renal safety of on-demand PrEP with TDF/FTC was good. The overall reduction and intermittent exposure to TDF/FTC may explain this good renal safety.
引用
收藏
页数:10
相关论文
共 27 条
[1]  
[Anonymous], 2008, ANRS scale to grade the severity of adverse events in adults
[2]   Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women [J].
Baeten, J. M. ;
Donnell, D. ;
Ndase, P. ;
Mugo, N. R. ;
Campbell, J. D. ;
Wangisi, J. ;
Tappero, J. W. ;
Bukusi, E. A. ;
Cohen, C. R. ;
Katabira, E. ;
Ronald, A. ;
Tumwesigye, E. ;
Were, E. ;
Fife, K. H. ;
Kiarie, J. ;
Farquhar, C. ;
John-Stewart, G. ;
Kakia, A. ;
Odoyo, J. ;
Mucunguzi, A. ;
Nakku-Joloba, E. ;
Twesigye, R. ;
Ngure, K. ;
Apaka, C. ;
Tamooh, H. ;
Gabona, F. ;
Mujugira, A. ;
Panteleeff, D. ;
Thomas, K. K. ;
Kidoguchi, L. ;
Krows, M. ;
Revall, J. ;
Morrison, S. ;
Haugen, H. ;
Emmanuel-Ogier, M. ;
Ondrejcek, L. ;
Coombs, R. W. ;
Frenkel, L. ;
Hendrix, C. ;
Bumpus, N. N. ;
Bangsberg, D. ;
Haberer, J. E. ;
Stevens, W. S. ;
Lingappa, J. R. ;
Celum, C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) :399-410
[3]   Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial [J].
Choopanya, Kachit ;
Martin, Michael ;
Suntharasamai, Pravan ;
Sangkum, Udomsak ;
Mock, Philip A. ;
Leethochawalit, Manoj ;
Chiamwongpaet, Sithisat ;
Kitisin, Praphan ;
Natrujirote, Pitinan ;
Kittimunkong, Somyot ;
Chuachoowong, Rutt ;
Gvetadze, Roman J. ;
McNicholl, Janet M. ;
Paxton, Lynn A. ;
Curlin, Marcel E. ;
Hendrix, Craig W. ;
Vanichseni, Suphak .
LANCET, 2013, 381 (9883) :2083-2090
[4]   Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service [J].
Drak, Douglas ;
Barratt, Hamish ;
Templeton, David J. ;
O'Connor, Catherine C. ;
Gracey, David M. .
PLOS ONE, 2019, 14 (01)
[5]   Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial [J].
Fonsart, Julien ;
Saragosti, Sentob ;
Taouk, Milad ;
Peytavin, Gilles ;
Bushman, Lane ;
Charreau, Isabelle ;
Hance, Allan ;
Goldwirt, Lauriane ;
Morel, Stephane ;
Mammano, Fabrizio ;
Loze, Benedicte ;
Capitant, Catherine ;
Clavel, Francois ;
Mahjoub, Nadia ;
Meyer, Laurence ;
Anderson, Peter L. ;
Delaugerre, Constance ;
Molina, Jean-Michel .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (02) :478-485
[6]   Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study [J].
Gandhi, Monica ;
Glidden, David V. ;
Mayer, Kenneth ;
Schechter, Mauro ;
Buchbinder, Susan ;
Grinsztejn, Beatriz ;
Hosek, Sybil ;
Casapia, Martin ;
Guanira, Juan ;
Bekker, Linda-Gail ;
Louie, Alexander ;
Horng, Howard ;
Benet, Leslie Z. ;
Liu, Albert ;
Grant, Robert M. .
LANCET HIV, 2016, 3 (11) :E521-E528
[7]   Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. [J].
Grant, Robert M. ;
Lama, Javier R. ;
Anderson, Peter L. ;
McMahan, Vanessa ;
Liu, Albert Y. ;
Vargas, Lorena ;
Goicochea, Pedro ;
Casapia, Martin ;
Guanira-Carranza, Juan Vicente ;
Ramirez-Cardich, Maria E. ;
Montoya-Herrera, Orlando ;
Fernandez, Telmo ;
Veloso, Valdilea G. ;
Buchbinder, Susan P. ;
Chariyalertsak, Suwat ;
Schechter, Mauro ;
Bekker, Linda-Gail ;
Mayer, Kenneth H. ;
Kallas, Esper Georges ;
Amico, K. Rivet ;
Mulligan, Kathleen ;
Bushman, Lane R. ;
Hance, Robert J. ;
Ganoza, Carmela ;
Defechereux, Patricia ;
Postle, Brian ;
Wang, Furong ;
McConnell, J. Jeff ;
Zheng, Jia-Hua ;
Lee, Jeanny ;
Rooney, James F. ;
Jaffe, Howard S. ;
Martinez, Ana I. ;
Burns, David N. ;
Glidden, David V. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (27) :2587-2599
[8]  
Hare C, 2019, 2019 26 C RETR OPP I
[9]   Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals [J].
Jotwani, Vasantha ;
Scherzer, Rebecca ;
Glidden, David V. ;
Mehrotra, Megha ;
Defechereux, Patricia ;
Liu, Albert ;
Gandhi, Monica ;
Bennett, Michael ;
Coca, Steven G. ;
Parikh, Chirag R. ;
Grant, Robert M. ;
Shlipak, Michael G. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 78 (02) :169-174
[10]   A New Equation to Estimate Glomerular Filtration Rate [J].
Levey, Andrew S. ;
Stevens, Lesley A. ;
Schmid, Christopher H. ;
Zhang, Yaping ;
Castro, Alejandro F., III ;
Feldman, Harold I. ;
Kusek, John W. ;
Eggers, Paul ;
Van Lente, Frederick ;
Greene, Tom ;
Coresh, Josef .
ANNALS OF INTERNAL MEDICINE, 2009, 150 (09) :604-612